Hematology: Azacitidine improves survival in myelodysplastic syndromes.
Rose
Michal G
MG
Comprehensive Cancer Center, Veterans Administration Connecticut Healthcare System, CT 06516, USA. michal.rose@va.gov
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006405:Hematology; D006801:Humans; D015337:Multicenter Studies as Topic; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016019:Survival Analysis; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
Lancet Oncol. 2009 Mar;10(3):223-32
19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
12011120
Leuk Lymphoma. 2008 Apr;49(4):690-5
18398735
J Clin Oncol. 2007 Aug 10;25(23):3503-10
17687155
N Engl J Med. 2006 Oct 5;355(14):1456-65
17021321
J Clin Oncol. 2002 May 15;20(10):2441-52
12011121
Blood. 2008 Jan 1;111(1):86-93
17893227
J Clin Oncol. 2011 May 20;29(15):1987-96
21483003
J Clin Oncol. 2009 Apr 10;27(11):1850-6
19255328
Blood. 1997 Mar 15;89(6):2079-88
9058730